Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Lang

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Current Opinion in Structural Biology|May 14, 2023
Recent breakthroughs in computational structural biology harnessing the power of sequences and structuresBálint Mészáros, Electa Park, Duccio Malinverni, et al.
Biochemical Society Transactions|September 20, 2012
Evolutionary selection for protein aggregationNatalia Sanchez de Groot, Marc Torrent, Anna Villar-Piqué, et al.
Nucleic Acids Research|November 14, 2023
Improved discovery of RNA-binding protein binding sites in eCLIP data using DEWSeqThomas Schwarzl, Sudeep Sahadevan, Benjamin Lang, et al.
BMJ Open Quality|September 17, 2019
Medic One Pediatric (MOPed) cards: standardising paramedic paediatric resuscitationBrandon Woods, Benjamin Lang, Carolyn Blayney, et al.
Thrombosis and Haemostasis|March 20, 2015
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranStephan Glund, Viktoria Moschetti, Stephen Norris, et al.
Expert Opinion on Investigational Drugs|November 5, 2016
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjectsChristopher Wynne, Mario Altendorfer, Ivo Sonderegger, et al.
Frontiers in Behavioral Neuroscience|October 9, 2023
Challenges and advanced concepts for the assessment of learning and memory function in miceBenjamin Lang, Pia Kahnau, Katharina Hohlbaum, et al.
Nucleic Acids Research|June 16, 2021
Matrix-screening reveals a vast potential for direct protein-protein interactions among RNA binding proteinsBenjamin Lang, Jae-Seong Yang, Mireia Garriga-Canut, et al.
Rheumatology and Therapy|July 1, 2018
Similar Pharmacokinetics of the Adalimumab (Humira<sup>®</sup>) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE<sup>®</sup>-AI and VOLTAIRE<sup>®</sup>-TAI): Phase 1, Randomized, Open-Label, Parallel-Group TrialsSteven Ramael, Benjamin Van Hoorick, Renger Tiessen, et al.
Frontiers in Immunology|December 6, 2021
Conserved Induction of Distinct Antiviral Signalling Kinetics by Primate Interferon Lambda 4 ProteinsCuncai Guo, Dorothee Reuss, Jonathon D Coey, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Current Opinion in Structural Biology|May 14, 2023
Recent breakthroughs in computational structural biology harnessing the power of sequences and structuresBálint Mészáros, Electa Park, Duccio Malinverni, et al.
Biochemical Society Transactions|September 20, 2012
Evolutionary selection for protein aggregationNatalia Sanchez de Groot, Marc Torrent, Anna Villar-Piqué, et al.
Nucleic Acids Research|November 14, 2023
Improved discovery of RNA-binding protein binding sites in eCLIP data using DEWSeqThomas Schwarzl, Sudeep Sahadevan, Benjamin Lang, et al.
BMJ Open Quality|September 17, 2019
Medic One Pediatric (MOPed) cards: standardising paramedic paediatric resuscitationBrandon Woods, Benjamin Lang, Carolyn Blayney, et al.
Thrombosis and Haemostasis|March 20, 2015
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranStephan Glund, Viktoria Moschetti, Stephen Norris, et al.
Expert Opinion on Investigational Drugs|November 5, 2016
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjectsChristopher Wynne, Mario Altendorfer, Ivo Sonderegger, et al.
Frontiers in Behavioral Neuroscience|October 9, 2023
Challenges and advanced concepts for the assessment of learning and memory function in miceBenjamin Lang, Pia Kahnau, Katharina Hohlbaum, et al.
Nucleic Acids Research|June 16, 2021
Matrix-screening reveals a vast potential for direct protein-protein interactions among RNA binding proteinsBenjamin Lang, Jae-Seong Yang, Mireia Garriga-Canut, et al.
Rheumatology and Therapy|July 1, 2018
Similar Pharmacokinetics of the Adalimumab (Humira<sup>®</sup>) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE<sup>®</sup>-AI and VOLTAIRE<sup>®</sup>-TAI): Phase 1, Randomized, Open-Label, Parallel-Group TrialsSteven Ramael, Benjamin Van Hoorick, Renger Tiessen, et al.
Frontiers in Immunology|December 6, 2021
Conserved Induction of Distinct Antiviral Signalling Kinetics by Primate Interferon Lambda 4 ProteinsCuncai Guo, Dorothee Reuss, Jonathon D Coey, et al.
Pageof 8